Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Macrogol** is the International Nonproprietary Name for polyethylene glycol, a non-absorbed synthetic polyether polymer used pharmacologically as an **osmotic laxative**. After oral administration, it retains water in the intestinal lumen, softening stool and increasing stool volume, which facilitates bowel movements; it does not act through a defined receptor target. The name is chemically non-specific because marketed products use different polymer molecular-weight ranges, most commonly macrogol 3350 or macrogol 4000, with or without electrolytes. Macrogol products are used for constipation and fecal impaction, while higher-volume macrogol-containing preparations are used for bowel cleansing before colonoscopy or surgery. ([ema.europa.eu](https://www.ema.europa.eu/en/documents/other/public-summary-evaluation-proposed-paediatric-investigation-plan-macrogol-3350-treatment-constipation_en.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol.